Scivision Biotech Inc. · TWSE:1786
Scivision Biotech — Investor Conference 2023
34 slides from Scivision Biotech's conference presentation, Aug 9, 2023
Slide 1: Investor Conference 2023
Investor Conference 2023 科妍生物科技股份有限公司 SciVision Biotech Inc. Dr. Chun Chang Chen .
Slide 2: Disclaimer
Disclaimer This slide contains our business prospect, financial condition and sales prognosis which are derived from our existing internal/external data analysis. The actual result of operations may differ from the expressed or implied in these forward-looking statements due to various reasons, incl
Slide 3: Outline
Outline 1. Company & Product &Technology Overview 2. Business Operation
Slide 4: About SciVision Biotech Inc.
About SciVision Biotech Inc. ◼ Established in 2001 ◼ Listed on TSE in 2013 (Code: 1786) ◼ Professional high-class, pharmaceutical-grade Hyaluronic Acid medical device production ◼ Two factories are located at No. 1, S. 1st Rd., and No. 9, S. 6th Rd., Qianzhen Dist., Kaohsiung City, Taiwan ◼ Received
Slide 5: Core Technologies
Core Technologies (Crosslinked Hyaluronic Acid Platform, CHAP ® ) Cross-linking Knowledge method Inspection ® The application of CHAP CHAP technology can be made into products of various types and applications Absorbable Single-injection Dermal Other new application adhesion barrier viscosupplement
Slide 6: Intellectual Property Protection of CHAP
Intellectual Property Protection of CHAP United States Taiwan Japan China EU
Slide 7: Core Products of SciVision
Core Products of SciVision Facial Aesthetics Geriatrics care Surgery Urinary
Slide 8: Market research on global market value and growth rate
Market research on global market value and growth rate Global market Applied field Items CAGR value in 2022 Facial Aesthetics Dermal Filler 5.5 billion 10.5 % Synovial Fluid Geriatrics Care 3.9 billion 7.3 % Supplement Absorbable Surgery 4.1 billion 9.8 % Adhesion Barrier Intravesical Urinary 1.3 bi
Slide 9: Classification of HA Dermal Filler
Classification of HA Dermal Filler Gel type vs Particle type Based on the gel type, HA facial dermal implant can be divided into monophasic type and biphasic type. The leading brand for each type is Juvederm from Allergan and Restylane from Galderma respectively. monophasic(Gel type) biphasic(Partic
Slide 10: HA Dermal Filler
HA Dermal Filler Monophasic Fillers Biphasic Fillers (Gel type) (Particle type) Product advantages ✓ High safety performance Product advantages ✓ Strong structural support ✓ High safety performance ✓ Shift resistance ✓ Smooth and natural ✓ Excellent viscoelasticity ✓ Easy operation ✓ Sufficient acti
Slide 11: Benchmark Comparison
Benchmark Comparison The texture of gel of ANiMERS is as smooth as that of Juvederm
Slide 12: Biphasic HA Fillers of SciVision are very supportive
Biphasic HA Fillers of SciVision are very supportive
Slide 13: Clinical Trials and Publications
Clinical Trials and Publications 1. A Guide to Cheek Augmentation: Single-Point Deep Injection of Hyaluronic Acid Filler at Midface in Close Proximity to Medial Suborbicularis Oculi Fat (SOOF) Area. Journal of Cosmetics, Dermatological Sciences and Applications. 2016 Jan 06(01):1-8. 2. Use of High-R
Slide 14: Collagen Stimulator
Future research and development direction Collagen Stimulator Stimulate collagen production Absorbable polymeric materials such as polymethyl methacrylate, short peptides, calcium hydroxyapatite, polylactic acid, or polycaprolactone induce fibroblasts to synthesize collagen. Implants of the polymeri
Slide 15: II. Synovial Fluid Supplement
II. Synovial Fluid Supplement 1 injection for 6 months 1 injection for 12 months Anti-free Radical Protection Type 1 injection for 6 months 3 injection for 6 months
Slide 16: Anti-free Radical Protection Type
Anti-free Radical Protection Type JETKNEE Synovial Fluid Supplement Product advantages ✓ 1 injection for 6 months ✓ Anti-free Radical Protection Type ✓ Free of animal origin ✓ Easy to operate
Slide 17: Degradation Rate
Degradation Test with ROS (H2O2) Jetknee+ H2O2 Degradation Rate *Pvalue JETKNEE, containing 2% HA with addition of Mannitol prolongs the protective effect of HA in the joints by removing free radicals.
Slide 18: Synovial Fluid Supplement
Synovial Fluid Supplement Global Product Treatment CAGR of Products category description treatments 1-injection Effect could be lasted regimen for more than half a (Long- year with administrating 10.2% acting) 1 syringe. 1 injection for 1 syringe per year Anti-free Radical 6 months Super Long-Acting
Slide 19: Clinical Trials and Publications
Clinical Trials and Publications 1. The effect of three weekly intra-articular injections of hyaluronate on pain, function, and balance in patients with unilateral ankle arthritis. J Bone Joint Surg Am. 2011 Sep 21;93(18):1720-6. 2. Changes of synovial fluid protein concentrations in supra-patellar
Slide 20: Future research and development direction
Future research and development direction Drug-containing Synovial Fluid Supplement repair damaged cartilage Quick anti- inflammatory pain relief Strengthens body tissue protection Prolong product efficacy
Slide 21: III. Absorbable Adhesion Barrier
III. Absorbable Adhesion Barrier Postsurgical adhesion Injured organ The fibrin acts like Adhesion or tissue a glue to seal the injury formation Inflammation Tendon, peripheral Gynecologic surgery nerve, joint surgery
Slide 22: III. Absorbable Adhesion Barrier
III. Absorbable Adhesion Barrier For gynecological For ligament, peripheral pelvic surgery nerve, joint surgery Product advantages Product advantages ✓ High Biocompatibility ✓ High Biocompatibility ✓ Easy to apply ✓ Easy to apply ✓ Shift resistance ✓ Shift resistance ✓ Long effective protection time
Slide 23: Clinical Trials and Publications
Clinical Trials and Publications 1. A resorbable hyaluronic acid hydrogel to prevent adhesion in porcine model under laparotomy pelvic surgery. J Appl Biomater Funct Mater. Jan-Dec 2021;19. 2. Crosslinked Hyaluronic Acid Gels for the Prevention of Intrauterine Adhesions after a Hysteroscopic Myomect
Slide 24: IV. Intravesical Instillation
IV. Intravesical Instillation
Slide 25: HYAURO Intravesical Instillation
HYAURO Intravesical Instillation Product Specification PACKAGE：50 mL per vial ACTIVE INGREDIENT: Sodium Hyaluronate 40mg DESCRIPTION The glycosaminoglycan (GAG) layer on the luminal surface of the bladder wall is the primary defense mechanism which can provide a protective barrier to against microor
Slide 26: Core Products of SciVision
Core Products of SciVision Facial Aesthetics Geriatrics care Surgery Urinary
Slide 27: Outline
Outline 1. Company & Product &Technology Overview 2. Business Operation
Slide 28: Profit & Loss-Consolidated
Profit & Loss-Consolidated Profit & Loss-Consolidated Unit:NT thousand dollars 2023/01/01~2023/06/30 2022/01/01~2022/06/30 Annual (except for EPS) (Reviewed) (Reviewed) growth rate Revenue 303,644 100% 232,578 100% 30.6% Cost of Goods Sold (94,272) -31% (86,850) -37% 8.5% Gross Profit 209,372 69% 14
Slide 29: Domestic and International Sales Ratio
Domestic and International Sales Ratio 2023 Jan.~Jun. & 2022 Jan.~Jun.
Slide 30: Product Portfolio Sales Ratio
Product Portfolio Sales Ratio 2023 Jan.~Jun. & 2022 Jan.~Jun.
Slide 31: Balance Sheet-Consolidated
Balance Sheet-Consolidated Balance Sheet-Consolidated 2023/06/30 2022/06/30 Unit:NT thousand dollars (Reviewed) (Reviewed) Cash and Cash Equivalents 680,975 31% 395,937 20% Accounts Receivable 117,042 5% 78,835 4% Inventories 95,165 4% 85,112 4% Current Financial Assets at Fair Value 58,348 - throug
Slide 32: Cash Flows-Consolidated
Cash Flows-Consolidated Cash Flows-Consolidated 2023/01/01~2023/06/30 2022/01/01~2022/06/30 Unit:NT thousand dollars (Reviewed) (Reviewed) From Operating Activities 99,324 69,164 Profit before tax 88,175 79,865 Depreciation & Amortisation 31,228 30,764 Net change in working capital (20,079) (41,465)
Slide 33: Healthy Cashflow and Expanding Profit
HEALTHY CASHFLOW AND EXPANDING PROFIT Revenue Gross and Operating Margin Million dollars Cash Generated From Operations Net Profit Before Interest And Taxes Million Million dollars dollars
Slide 34: Our Vision
Our Vision Science Creates Better Visions